
Batch-Documented
HPLC-Verified
Independent Assay
Same Reorder Price
GLPs · TRIPLE GLP-1/GIP/GLUCAGON AGONIST
RT3 30 mg
Lyophilized vial · 39 AA
— Vial size
Per vial
Select your pack size
SingleShips within 48 hours from San Antonio
UPS Ground · tracked + insured · released after independent lab testing
- Purity Guarantee. If a batch fails our ≥99% HPLC standard, full refund + replacement.
- Batch certificate in the COA library, anytime, free
- Same reorder price — forever, no upcharge
$169.99
Single
RT3 in brief
RT3 is a synthetic triple GIP, GLP-1 and glucagon receptor agonist peptide, studied in phase 2 and phase 3 research trials of body weight, glycemic control and liver fat in adults with obesity or type 2 diabetes. RT3 is not FDA-approved; it is investigational. Supplied for research use only.
— About this compound
RT3.
Class · Triple agonist at GIP, GLP-1, and glucagon receptors (synthetic peptide)
Origin. First publicly characterized by Coskun et al. in 2022 as the next-generation evolution of the dual-incretin concept embodied in TZ2.
RT3 is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation.
The compound is currently in late-stage clinical investigation for obesity and type 2 diabetes. Public literature is concentrated in Phase 1–2 trial reports and preclinical pharmacology.
— Common research applications
- Triple-incretin pharmacology
- Energy expenditure research
- Comparative incretin-agonist studies
- Metabolic flux models
— Mechanism
How it's been studied.
Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models.
Mechanism descriptions reflect findings reported in the preclinical and basic-research literature. They are not clinical conclusions and not statements of therapeutic effect.
— The Chemistry
The numbers, plainly.
CAS
—
Molecular weight
5419 Da
Formula
—
Sequence
—
Format
Lyophilized powder
Vial dose
30 mg
Purity (HPLC)
≥99%
Amino acids
39
Half-life
~6 days (early clinical pharmacokinetic reports).
Solubility
Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.
View the July 2026 batch certificate for RT3 30 mg → or browse every certificate.
— Why Merit
The supplier difference.
How Merit compares to the two alternatives most research buyers consider for RT3.
Comparison reflects published facility status and standard industry practice. Compounding pharmacy availability of research peptides varies by jurisdiction.
— How it's made
From compound to your shelf.
Every Merit batch follows the same documented path. Five steps, every one verifiable.
- 01
Sourcing
Compound starts as a research-grade API.
Active pharmaceutical ingredient sourced from FDA-registered manufacturers. Identity confirmed against reference standard before any compounding begins.
- API from FDA-registered manufacturers
- Identity verified against reference standard
- Chain of custody documented
- 02
Compounding
Sterile-filled in a US cleanroom.
Lyophilized in a cleanroom at our US facility. The powder format gives ≥24 months sealed stability — no cold-chain shipping required.
- Licensed US facility
- Batch-documented manufacturing process
- Lyophilized powder for transit stability
- 03
Verification
Every batch HPLC-tested.
Reverse-phase HPLC-UV (UV/MS for higher-MW peptides) confirms identity and purity for every batch before it leaves the lab. The chromatogram is archived.
- Reverse-phase HPLC, per-batch
- ≥99% purity floor — every batch
- Chromatogram archived for every batch
- 04
Release
The batch is released against an independent assay.
No batch ships until an independent laboratory has returned its identity and purity results and the certificate is published in the COA library.
- Independent laboratory on every batch
- Certificate published before sale
- Every certificate is in the public COA library
- 05
Dispatch
Ships from San Antonio in 48 hours.
Sealed vials with a QR code on the label that opens the COA library. Order before 2pm CT Monday–Thursday for same-day dispatch. UPS Ground, tracked + insured.
- 48hr dispatch from San Antonio, TX
- QR code on every vial label
- UPS Ground, tracked + insured
Every step above can be verified for any specific batch by emailing support@meritsciences.com with your order number.
— Research references
The published record.
Peer-reviewed work cited in the public scientific literature. Links resolve to PubMed or the publisher of record.
- 01
Coskun T, Urva S, Roell WC, et al. · Cell Metabolism · 2022
- 02
Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023
- 03
Rosenstock J, Frias J, Jastreboff AM, et al. · The Lancet · 2023
Inclusion of a reference does not constitute a clinical claim or recommendation.
— The Batch Note
Triple agonist, newer than TZ2. Limited literature but increasing research interest.
Merit Sciences Lab Team
Independently assayed · Licensed US facility · Ships from San Antonio, TX
— Go deeper
Mechanism, published research and peer-reviewed references for RT3, with no product attached.
— Common Questions
Got questions.
Is RT3 FDA-approved?+
RT3 is not FDA-approved; it is investigational. Supplied for research use only.
How is each batch of RT3 tested?+
Every batch is tested by an independent laboratory for identity and HPLC purity before it is listed. Merit identifies batches by date: the current certificate for RT3 30 mg is the July 2026 batch, 99.27% purity by HPLC, published at meritsciences.com/coa/COA-2026-REQNW5. The QR code on each vial opens the same page. Open the July 2026 batch certificate →
What does the published research on RT3 show?+
In a 48-week phase 2 trial in 338 adults with obesity (NEJM 2023), the top treatment arm reported a mean body-weight change of about minus 24.2% versus about minus 2.1% on placebo. A separate phase 2 trial in adults with type 2 diabetes (Lancet 2023) reported lower HbA1c and body weight than placebo. The RT3 monograph at meritsciences.com/library/rt3 lists the references. Read the RT3 monograph →
What is RT3?+
RT3 is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation.
How does RT3 work?+
Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models.
What class of compound is RT3?+
RT3 is classified as triple agonist at GIP, GLP-1, and glucagon receptors (synthetic peptide).
What is the reported half-life of RT3?+
~6 days (early clinical pharmacokinetic reports).
Why does Merit ship lyophilized?+
Lyophilized (freeze-dried) material is stable in sealed storage: ≥24 months at -20°C. Peptides held in solution degrade far faster, so every compound ships as a dry powder in a sealed vial.
What does "independently assayed" actually mean?+
Every batch is tested by a laboratory independent of the facility that made it, and the certificate is published before the batch is listed. You read the same identity and purity figures we do, which is what separates Merit from a reseller catalog.
How fast does it ship?+
48 hours from order to dispatch, Monday through Thursday. UPS Ground, tracked + insured. From San Antonio, TX, most US addresses receive within 3-5 business days.
— Talk to a Pharmacologist
Question we didn't answer?
Our team answers compound and batch questions the same business day. No bots, no tickets.
Email the team →— Same Family
